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Influenza is one of the most important illnesses in the modern world, causing great public 
health losses each year due to the lack of medication and broadly protective, long-last-
ing vaccines. The development of highly immunogenic and safe vaccines is currently 
one of the major problems encountered in efficient influenza prevention. DNA vaccines 
represent a novel and powerful alternative to the conventional vaccine approaches. To 
improve the efficacy of the DNA vaccine against influenza H5N1, we inserted three 
repeated kappa B (κB) motifs, separated by a 5-bp nucleotide spacer, upstream of the 
cytomegalovirus promoter and downstream of the SV40 late polyadenylation signal. 
The κB motif is a specific DNA element (10pb-long) recognized by one of the most 
important transcription factors NFκB. NFκB is present in almost all animal cell types and 
upon cell stimulation under a variety of pathogenic conditions. NFκB is released from 
IκB and translocates to the nucleus and binds to κB sites, thereby leading to enhanced 
transcription and expression of downstream genes. We tested the variants of DNA 
vaccine with κB sites flanking the antigen expression cassette and without such sites in 
two animal models: chickens (broilers and layers) and mice (BALB/c). In chickens, the 
variant with κB sites stimulated stronger humoral response against the target antigen. In 
mice, the differences in humoral response were less apparent. Instead, it was possible 
to spot several gene expression differences in the spleens isolated from mice immunized 
with both variants. The results of our study indicate that modification of the sequence 
outside of the sequence encoding the antigen might enhance the immune response 
to the target but understanding the mechanisms responsible for this process requires 
further analysis.
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inTrODUcTiOn
DNA vaccines were introduced over two decades ago. This very promising technique relies on the 
production of an antigen by the cells of an immunized host after the introduction of a genetically 
engineered expression cassette for this antigen and, as a consequence, induction of humoral and 
cellular immune responses (1). Despite multiple advantages, the DNA vaccines have apparent 
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pitfalls that need to be addressed before being applied for vet-
erinary or clinical purposes (2). One of the factors limiting the 
effectiveness of DNA vaccine is the transport of the plasmid 
DNA to the nucleus through the nuclear envelope. The links 
between the transfer of non-viral DNA to the nucleus and the 
transgene expression level has been mostly explored in relation 
to therapeutic purposes such as gene therapy and anticancer vac-
cines [for reviews, see Ref. (3–6)]. Recently, it was suggested that 
various proteins containing a nuclear localization signal might 
play a role in the intracellular trafficking of plasmid DNA to the 
nucleus and that the microtubule network and motors might be 
required for this process (7). This suggestion is in agreement with 
earlier observations that either covalent attachment of nuclear 
proteins to the plasmid or the presence of cis-binding sites for 
nuclear proteins, such as transcription factors, in the DNA of the 
transfected plasmid might improve the efficiency of non-viral 
gene transfer (8, 9).
The most promising approaches involve the use of NF-κB 
(10–12). The transcription factors of the NF-κB family contain 
an evolutionarily conserved region at their N-terminus named 
the Rel homology domain (RHD), which is responsible for 
dimerization and binding to the kappa B (κB) motif in DNA 
(13–15). Inactive NF-κB dimers are sequestered in the cyto-
plasm because of their association with the inhibitor of NF-κB 
(IκB). Upon stimulation, IκB is phosphorylated by the action 
of a specific IκB kinase, ubiquitinated, and degraded in the 
proteasome. The released NF-κB dimers enter the nucleus, bind 
to κB sites in the promoters of the target genes, and initiate (or 
enhance) their transcription (16). The observation that the κB 
motif (5′-GGGGACTTTCC-3′) can augment nuclear entry of 
modified vectors and increase the expression level of reported 
genes in various transfected human cells was first published in 
2001 (12). Similar experiments were later performed by other 
researchers, who observed positive correlations between the 
number of κB sites (i.e., 5, 10, or 20 tandem repeats) upstream the 
cytomegalovirus (CMV) promoter and the transgene expression 
level in transfected cells of the murine carcinoma colon 26 line 
(17). Other researchers designed DNA vectors with several κB 
sites separated by the optimized 5-bp spacer (5′-AGCTG-3′) and 
used luciferase as a reporter protein to monitor in vivo the influ-
ence of these sites on the level of transgene expression (10, 11). 
They found higher luciferase activity in mice transfected with the 
plasmid containing the expression cassette for luciferase flanked 
by the sequence consisting of three repeated κB sites separated 
by spacers than in mice transfected with the plasmid containing 
the same cassette but without κB sites. Understanding of the 
mechanisms responsible for the higher expression of transgenes 
flanked by κB sites in comparison to transgenes without such 
motifs could help in the translation of this observation into 
knowledge needed for the purposes of the effective DNA vaccine 
development.
Influenza virus is an important pathogen, causing seasonal 
and sudden pandemics in humans and its avian variants can be 
devastating for domestic poultry. Moreover, zoonotic transmis-
sion of highly pathogenic avian influenza viruses, like H5N1, 
has been reported regularly. Vaccination is the most promising 
strategy to control the virus, but traditional vaccines are not 
very useful in the case of new emerging strains, and therefore, 
the development of innovative, new-generation vaccines is an 
urgent need.
We have previously published several papers describing our 
work on development of DNA vaccine against H5N1 influenza 
(18–20). In this work, we tested two types of DNA vaccine, one 
containing the κB sites (in triplicates; with 5-bp spacers) flank-
ing the antigen expression cassette and the other without such 
sites, in two animal models, chickens and mice. Both plasmids 
had the same antigen expression cassette encoding full-length 
hemagglutinin (HA) from influenza virus strain A/swan/
Poland/305-135V08/2006(H5N1). Experiments with chickens, 
the natural host of avian influenza virus, focused on the compari-
son of humoral responses in sera. In mice, not only the humoral 
response in serum, but also the level of cytokines secreted by sple-
nocytes and the population of cytotoxic T cells (Tc) and helper 
T cells (Th) were examined. Moreover, the spleen transcriptome 
profiles of the selected mice groups were examined. The results 
indicated that in chicken the humoral response was slightly better 
after immunization with the plasmid containing the κB sites than 
with the plasmid without such sites. In mice, the difference was 
much less apparent.
MaTerials anD MeThODs
Plasmid construction
The K3/pCI plasmid, containing the full-length cDNA of HA 
from the highly pathogenic influenza virus strain A/swan/
Poland/305-135V08/2006(H5N1, clade 2.2), has been described 
before as a long variant of DNA vaccine (18). The 3NF/pCI 
plasmid contains the same expression cassette, which is addition-
ally flanked by 45-bp sequences. One is located upstream of the 
CMV promoter, and the second is located downstream of the 
SV40 late polyadenylation signal. Each 45-bp sequence contains 
three repeats of NF-κB-binding sites (5′-GGGACTTTCC-3′) 
separated by the optimized spacer (5′-AGCTG-3′). The NFGK/
pCI plasmid consists of the identical 45-bp sequences but they 
flank the cassette with the modified cDNA sequence of HA, pre-
sent in previously described GK/pCI plasmid (20). The plasmids 
were propagated in Escherichia coli (DH5α strain) and isolated 
using the NucleoBond® PC 10000 EF giga-scaled purification kit 
(Macherey-Nagel, 740548). Before immunization, the plasmid 
DNA, suspended in PBS, was mixed with Lipofectin® (18292-037, 
Invitrogen™) in a 6:1 ratio (DNA:Lipofectin [v/v]), as described 
before (18).
immunization of animals and  
ethic statement
Chickens
Broiler chickens Ross 308 and layer chickens Rosa 1 were pur-
chased from a local commercial brooder on the day of hatching 
and were maintained at an experimental poultry house under 
standard bedding conditions. Animals were fed once a day and 
had free access to water. At the end of the experiment, the animals 
were humanely euthanized. Chickens were immunized intramus-
cularly with 60 µg of plasmid in final volume of 100 µl and blood 
TaBle 1 | Details of the immunization experiments.
animal model experiment nr (chicken type; dose) group size (n=) Days of treatmentsa
immunization Blood collection spleen collection
Chickens Experiment 1 (layers; 60 µg) K3/pCI 6 7, 21 21, 28, 35 –
3NF/pCI 6
pCI 2
Experiment 2 (broilers; 60 µg) K3/pCI 10 7, 21 21, 35 –
3NF/pCI 10
pCI 4
Experiment 3 (layers; 60 µg) K3/pCI 10 7, 21 35 –
3NF/pCI 10
NFGK/pCI 10
pCI 3
Mice Experiment 1 (20 µg) K3/pCI 6 35, 49 49, 56, 63 63
3NF/pCI 7
NFGK/pCI 7
pCI 2
Experiment 2 (20 µg) K3/pCI 8 35, 49 49, 56, 63 63
3NF/pCI 8
NFGK/pCI 8
pCI 7
Experiment 3 (20 µg) K3/pCI 3 35, 49 47, 52 52
3NF/pCI 3
pCI 2
aThe numbers refer to the day of life of the animals.
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samples were collected from the wing vein. Two doses of vaccine 
were administered at 7th and 21st days of life.
Mice
Specific pathogen-free BALB/c female mice were maintained at 
the experimental facility at the Mossakowski Medical Research 
Centre, Polish Academy of Sciences (Warsaw) under a 13-h 
light/11-h dark cycle with free access to water and standard 
mouse diet. All groups were immunized intramuscularly with 
20 µg of plasmid in final volume of 50 µl and the blood samples 
were collected from a left ventricle of heart. Two doses of vaccine 
were administered at 35th and 49th days of life. The schedule of 
chickens and mice immunization experiments is summarized in 
Table 1.
All efforts were made to minimize suffering. The experi-
ments with chickens were approved by the Second Local Ethical 
Committee for Animal Experiments at the Medical University 
of Warsaw, Permit Number 17/2009. The experiments of mice 
immunization were approved by the Fourth Local Ethical 
Committee for Animal Experiments at the National Medicines 
Institutes, Permit Number 03/2014.
elisa and antibody Titers
Chickens
The ELISA was performed as described earlier (18). Shortly, the 
MediSorp Surface (Nunc, UK) plates were coated with 300  ng 
of the recombinant homologous H5 HA antigen (obtained in 
baculovirus system; Oxford Expression Technologies, UK) 
and the bound IgY were detected with goat anti-chicken IgY 
(Fc-specific)-HRP (Pierce/Thermo Scientific, USA). For the 
determination of IgY endpoint titers, twofold serial dilutions (in 
a range of 10−3–10−6) of chicken sera collected on day 35 were 
analyzed using the ELISA protocol. The absorption curves were 
made using Gen5 Data Analysis Software (BioTek Instruments, 
Inc.), and the highest dilution giving a specific positive result was 
determined for each serum. The reciprocal of such dilution was 
defined as the endpoint serum titer.
Mice
Sera from immunized mice were tested for antibodies directed 
against homologous H5 HA by a one-dilution indirect ELISA 
using MaxiSorp Surface (Nunc, UK) plates coated with 300 ng of 
recombinant H5 HA (obtained in the baculoviral system; Oxford 
Expression Technologies, UK). Alkaline phosphatase-conjugated 
goat anti-mouse IgG (Sigma-Aldrich) was used as the secondary 
antibody.
hemagglutination inhibition (hi)
Hemagglutination inhibition tests were performed according to 
the OIE standard procedures using the heterologous hemagglu-
tinating antigen prepared from the low pathogenic H5N2 strain 
A/chicken/Belgium/150/1999 (DG Deventer, Netherlands). 
The 25-µl aliquots of serial twofold dilutions (from 1:8 to 
1:512) of sera in PBS were added to an equal volume of HA 
antigen containing four HA units. After incubation (25  min) 
in V-bottom microtiter plates at room temperature (RT), 25 µl 
of a 1% suspension of chicken red blood cells was added and 
incubated for 25 min at RT. HI titers are defined as the recip-
rocal of the highest dilution of sera that completely inhibited 
hemagglutination.
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cytokine Production by Mouse 
splenocytes and Percentage of Tc  
and Th cells in spleens
Immunized and control mice were euthanized 2  weeks after 
the boost dose (day 63) and their spleens were harvested. For 
determining the cytokine production and percentage of Tc 
and Th, splenocytes were prepared from spleen isolated from 
three randomly selected mice immunized in Experiment 2. The 
spleen cells suspensions were washed in RPMI-1640 medium 
(Sigma-Aldrich) and treated for 5 min with lysis buffer (Becton-
Dickinson, Franklin Lakes, NJ, USA) in order to remove red blood 
cells. To determine the levels of cytokines in culture supernatants 
(Experiment 1 and Experiment 2), the cells (2 ×  106 per well) 
were incubated in 96-well plates (Corning, NY, USA) in complete 
RPMI-1640 without any supplement (negative control), with 
recombinant H5 HA protein (Oxford Expression Technologies, 
UK) (10  µg/ml) or with concanavalin A (5  µg/ml). Cells were 
incubated for 72  h (37°C, 5% CO2) and centrifuged (10  min, 
1,000  rpm, 4°C). The level of cytokines was quantified in the 
collected supernatants using the Cytometric Bead Array Mouse 
Th1/Th2/Th17 Cytokine Kit (Becton-Dickinson) according to the 
manufacturer’s instructions and a FacsVERSE™ flow cytometer 
(Becton-Dickinson).
For determining the levels of CD8+ (Tc), CD4+ (Th) cells 
and their corresponding activated subpopulations: CD25+ (Tc), 
CD69+ (Tc), CD25+ (Th), and CD69+ (Th) splenocytes (1 × 106 
per probe) were incubated 30  min on ice with the following 
monoclonal antibodies (Becton-Dickinson): PerCP rat anti-
mouse CD4, FITC rat anti-mouse CD8, APC rat anti-mouse 
CD25, and FITC rat anti-mouse CD69. After incubation, the 
cells were washed three times, resuspended in the Stain Buffer 
(Becton-Dickinson), and examined by flow cytometry using 
FacsVERSE™ flow cytometer (Becton-Dickinson). The levels of 
Tc and Th were determined in the Laboratory of Flow Cytometry, 
Faculty of Biology University of Warsaw.
rna isolation and Microarray analysis
Microarray expression analysis was performed using the 
Affymetrix Gene Atlas system according to the manufac-
turer’s instructions. RNA was isolated from three independ-
ent individuals per treatment (K3/pCI and 3NF/pCI) or two 
independent control individuals (pCI), 3 days after the boosted 
vaccination; 100 ng of total RNA that passed the initial qual-
ity control screen was then prepared for Affymetrix whole 
transcriptome microarray analysis using the Ambion® WT 
Expression Kit (4411973). Prepared samples were hybridized 
to the Affymetrix® Mouse Gene 2.1 ST Array Strip (Affymetrix, 
Santa Clara, CA, USA). The microarrays were scanned with the 
Affymetrix GeneAtlas Scanner, and the intensity signals for each 
of the probe sets were written by Affymetrix software into CEL 
files. The CEL files were imported into Partek Genomic Suite 
v 6.6 software with the use of Robust Multiarray Averaging. 
During this step, a background correction was applied based 
on the global distribution of the PM (perfect match) probe 
intensities and the affinity for each of the probes (based on 
their sequences) was calculated. Then, the probe intensities 
were quantile normalized (21), log2 transformed, and the 
median polish summarization to each of the probe sets was 
applied. Qualitative analysis was the performed, e.g., principal 
components analysis, in order to identify outliers and artifacts 
on the microarray. After quality check, the three-way ANOVA 
model using Method of Moments (22) was applied to the data, 
which allowed us to create lists of significantly and differentially 
expressed genes between biological variants (with the cutoff 
values: p value <0.05, 1.4 >fold change >−1.4). Functional 
analysis of the obtained lists of the genes was performed in 
Ingenuity Pathway Analysis (Ingenuity Systems, Redwood City, 
CA, USA, http://www.ingenuity.com). The microarray data 
were deposited in Gene Expression Omnibus repository under 
the accession number GSE101747.
real-time Pcr
In order to validate the microarray data, the gene expression level 
of the selected genes was determined using the same samples 
of RNA as those used for microarray analysis. The cDNA was 
obtained from 1.2 µg of total RNA using the Maxima H Minus First 
Strand cDNA Synthesis Kit (Thermo Scientific) with Oligo(dT)18 
primers and was then used as the template in RT-qPCR using 
Thermo Scientific Luminaris Color HuGreen qPCR master mix 
(Thermo Sceintific). PCR was performed using the PikoReal™ 
Real-Time PCR System (Thermo Scientific). Assays contained 
the cDNA template diluted 20-fold. A 10-min hot-start activation 
at 95°C was followed by 40 cycles of 15 s of denaturation at 95°C, 
30 s of annealing at 60°C, and 30 s of extension at 72°C followed 
by dissociation analysis (60–95°C). Relative gene expression was 
calculated according to the 2−ΔΔCt method using TAF8 or PGK1 
as the reference gene. The list of used primers is in Table S1 in 
Supplementary Material.
statistical analysis
Non-parametric tests, such as Kruskal–Wallis (for the compari-
son of multiple groups) or Mann–Whitney U (for the comparison 
of two groups) that are components of Statistica 12 (StatSoft, 
Poland), were used for statistical analysis of the results of the 
following assays: ELISA, HI, cytokines production, and percent-
age of immune cells. The groups were considered significantly 
different if at last one of the tests was positive (p <  0.05). The 
significance of the observed changes in RT-qPCR was calculated 
by REST-MSC (23).
resUlTs
chickens response to the  
Tested Variants of Dna Vaccine
The effectiveness of the three variants of DNA vaccine against 
H5N1 was tested first in chickens, the natural host of influenza 
virus. The 3NF/pCI (and NFGK/pCI used only in Experiment 3) 
plasmids contained κB sites, while the K3/pCI plasmid did not 
contain such sites. The variants of the DNA vaccine were tested 
in chickens in three independent experiments, using either layers 
or broilers (Table 1). The results of the one-dilution ELISA and 
the HI tests are shown in Figures 1A,B, respectively. Antibody 
FigUre 1 | Humoral response of chickens to the tested variants of the DNA vaccine. (a) The results of the one-dilution ELISA test shown for individuals with 
medians and the 10th and 90th percentiles indicated for each group. All sera were diluted 200-fold. Statistically significant differences (p < 0.05) are marked by 
asterisks. (B) The individual HI titers and medians in each group (only for day 35) are shown as log2. Sera with undetected antibody levels were given an arbitrary 
value of 1. (c) The endpoint titers of anti-H5 hemagglutinin antibodies (day 35) of each group from Experiments 1 and 2. Data are presented as mean values with 
SD; geometric means are indicated in the brackets. Statistically significant differences (p < 0.05) are marked by asterisks.
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levels in the 3NF/pCI group detected by ELISA were significantly 
higher than in the K3/pCI group at all three analyzed time points 
(days 21, 28, and 35) in Experiment 1 and at one of two analyzed 
time points (day 35) in Experiment 2. In Experiment 3, the 
group immunized with NFGK/pCI vaccine was also included. 
In contrast to the results obtained in Experiments 1 and 2, the 
differences between groups in Experiment 3 were statistically 
insignificant on day 35; sera from the other time points are not 
available (Figure 1A). It is worth to notice that the medians in 
both groups were lower in Experiment 3 than in the previous 
experiments, suggesting the overall lower effectiveness of this 
vaccination trial.
In all experiments, the HI test was performed only with sera 
collected 2  weeks after the booster (day 35) using an H5N2 
commercial antigen. The results shown in Figure  1B indicate 
that 3NF/pCI groups had always highest median HI than the 
other groups, although the applied non-parametric tests failed to 
confirm a statistical significance of the observed difference.
FigUre 2 | Immune response of mice to the tested variants of the DNA vaccine. The results of the one-dilution ELISA test shown for individuals with medians and 
the 10th and 90th percentiles indicated for each group, where applicable (Experiments 1 and 2). All sera were diluted 100-fold. Statistically significant differences 
(p < 0.05) are marked by asterisks.
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The endpoint titers of anti-H5 HA antibody were  determined 
using sera from the final blood collection (35th day) in 
Experiments 1 and 2 (Figure 1C). All sera from chickens immu-
nized with 3NF/pCI reached titers above 104 and the majority had 
titers above 105. Moreover, the highest titer after immunization 
with 3NF/pCI was 3.4 × 105 and 2.2 × 105 in Experiment 1 (lay-
ers) and 2 (broilers), respectively (Figure S1 in Supplementary 
Material). By contrast, titers in groups K3/pCI were visibly lower 
and this difference was particularly appreciable in Experiment 1. 
In Experiment 2, titers of high responders were similar in both 
groups. The highest titer of K3/pCI was 7.2 × 104 in Experiment 
1 and 2.1 × 105 in Experiment 2. In summary, addition of κB sites 
apparently improved immunogenicity of the vaccine in chicken 
model.
Mice responses to the Tested  
Dna Vaccine Variants
The experiments with mice were performed independently to 
verify the effectiveness of the three tested variants (K3/pCI, NF/
pCI, and NFGK/pCI) of the DNA vaccine. The schedule and 
other details of the experiments are provided in Table  1. The 
level of anti-H5 HA antibodies in the sera of immunized mice 
was monitored by one-dilution ELISA (Figure 2). The values for 
individuals, medians, and the 10th–90th percentiles are shown 
for each group at each time point. Although the medians for 
the NFGK/pCI group were in several cases higher than in the 
corresponding K3/pCI and 3NF/pCI groups, the statistically 
significant differences were observed only in Experiment 1 at the 
56th day (between K3/pCI and NFGK/pCI) and in Experiment 
2 at the 63rd day (between K3/pCI and 3NF/pCI; also between 
3NF/pCI and NFGK/pCI).
In order to further explore the differences between the mice 
groups, the levels of cytokines produced by the stimulated in vitro 
splenocytes (Table 2) and the population of Tc (CD8+) and Th 
(CD4+) cells in the spleens (Table 3) have been assessed.
As indicated in Table 2, higher average level of IFN-γ in K3/
pCI than NFGK/pCI and 3NF/pCI was observed, while the aver-
age level of TNF was similar in K3/pCI and 3NF/pCI and slightly 
lower in NFGK/pCI. Unfortunately, the differences between the 
groups did not pass the statistical significance tests. Secretion of 
IL-2, IL-6, IL-4, IL-10, and IL-17a in all tested group was at the 
limit of detection (not shown). No secretion of TNFα and a very 
low secretion of IFN-γ were observed in the culture of stimulated 
splenocytes isolated from the control group vaccinated with the 
empty pCI vector (not shown).
As indicated in Table 3, all vaccinated groups had higher aver-
age percentage of Tc cells as compared to the control group (pCI). 
The percentage of Tc CD25+ cells was higher in all immunized 
groups, while the percentage of Tc CD69+ was higher in all groups 
but not in 3NF/pCI. Similarly, all vaccinated groups had higher 
percentage of Th, Th CD25+, and Th CD69+, in the spleens than 
the control (pCI) group. The highest average values of CD69+ 
(13.2%), CD25+ (5.3%), and CD69+ (5.6%) were in the NFGK/
pCI group; however, the large SD values do not allow to qualify 
these values as significantly different.
More differences between the two variants (K3/pCI and 3NF/
pCI) of the tested DNA vaccine were revealed by transcriptional 
profiling of the mice spleens isolated on day 52 (3 days after the 
booster) from mice immunized in Experiment 3. The analysis 
was limited to those 180 genes that had at least a ±1.4-fold 
difference (p <  0.05) in at least one of the groups immunized 
with the DNA vaccine in comparison to the pCI group (Table 
S2 in Supplementary Material; Figure 3A). The 3NF/pCI group 
had an apparently higher percentage (41%) of downregulated 
genes than the K3/pCI group (23%) and lower percentage of 
upregulated genes: 59% in 3NF/pCI in comparison to 77% in K3/
pCI. Further analysis failed to identify any significantly changed 
TaBle 2 | Cytokine levels produced by stimulated splenocytes isolated from the 
mice immunized with the tested variants of the DNA vaccine.
iFnγ (pg) TnF (pg)
K3/pCI 1,236 ± 333 61 ± 32
3NF/pCI 960 ± 274 65 ± 30
NFGK/pCI 964 ± 520 53 ± 22
The results are means (in bold) from three individuals (n = 3) with SDs indicated.
TaBle 3 | The percentage of cytotoxic T cells (Tc) and helper T cells (Th) and their subpopulations in mice spleens.
Dna vaccine Percentage of the indicated cells in the pull of isolated splenocytes
Tc Th
cD8+ cD8+cD25+ cD8+cD69+ cD4+ cD4+cD25+ cD4+cD69+
K3/pCI 26.9 ± 3.17 5.3 ± 0.65 8.2 ± 1.18 13.8 ± 0.4 3.9 ± 0.60 4.1 ± 0.43
3NF/pCI 25.0 ± 1.15 4.8 ± 0.15 7.7 ± 0.25 13.3 ± 1.37 3.0 ± 0.40 3.7 ± 0.40
NFGK/pCI 26.7 ± 0.65 5.4 ± 2.26 13.2 ± 9.00 13.4 ± 1.40 5.3 ± 3.76 5.6 ± 4.00
pCI 24.4 ± 1.60 3.9 ± 0.10 7.8 ± 0.23 12.7 ± 0.45 2.8 ± 0.25 3.3 ± 0.26
The results are means (in bold) from three individuals with SDs indicated.
FigUre 3 | Transcriptomic changes in the spleens of mice immunized with K3/pCI and 3NF/pCI in comparison to the group that received the empty vector (pCI). 
(a) Venn diagrams of upregulated and downregulated genes. (B) Results of RT-qPCR for selected genes. The significant changes of the expression (p < 0.05) in 
comparison to pCI group are indicated by the asterisks. Data are presented as mean values of three technical repeats for each sample with SD, calculated for all 
mice in a group (two mice in the control group and three mice in each experimental group were tested).
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immune-related function or pathway in the selected set of genes. 
Interestingly, six genes encoding miRNA were upregulated in the 
K3/pCI group, but only two of them (miR-669o-5p and miR-709) 
were also upregulated in the 3NF/pCI group. Moreover, miR-
181b-1 was downregulated only in 3NF/ pCI group, while miR-
1186 was downregulated only in K3/pCI. The differences can be 
also observed in the immunoglobulins transcripts, where few 
of them were downregulated in K3/pCI (Igkv13-84, Igkv2-112, 
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Igkv3-5, Igkv4-56, Igkv4-74) and none was changed in the 3NF/
pCI group (Table S2 in Supplementary Material).
Several genes (Apol11b, Lyst, HMGA1, Ifi44, IL-1A; the last 
two genes were not significantly changed in microarrays data) 
were selected for validation of expression by quantitative real-
time PCR. The significant differences between the groups were 
observed only for Apol11b (upregulated in both K3/pCI and 
3NF/pCI group) and Lyst (downregulated only in 3NF/pCI). The 
results of RT-qPCR analysis are shown in Figure 3B.
Summarizing the above results, due to the high individual 
variability, we do not have strong evidence to conclude that addi-
tion of ĸB sites improves the immunogenicity of the vaccine in 
mouse model.
DiscUssiOn
We demonstrate for the first time in two animal models that 
the binding sites for NF-κB might improve the efficacy of a 
DNA vaccine against influenza. It is known that κB motifs can 
augment nuclear entry of modified vectors and increase the 
expression level of reported genes in various transfected cells 
(10–12). The NF-κB proteins and κB sites are evolutionarily 
conserved and similar signaling pathways are found in mice 
and chickens (16, 24–26). It has been shown that RHD, p50, is 
particularly highly conserved between chicken and mammalian, 
and in vitro-synthesized, truncated chicken’s p105 protein (pre-
cursor of p50 protein), containing sequences that correspond to 
the predicted p50 protein, were able to bind the DNA fragment 
with the consensus κB site in an electrophoretic mobility shift 
assay (27). Other researchers demonstrated in vitro that human 
NF-κB/Rel-like proteins can bind to the κB-like sequence in the 
promoter of the gene encoding chicken lysozyme (26). The κB 
sites used in this work are similar to that found in the promoter 
of the gene encoding Igκ light chain in human and in the LTR 
of HIV-1.
Also, numerous studies confirmed that codon optimization to 
the codon bias of the antigen improves the efficacy of DNA vac-
cine. Several studies with mammalian cells suggest that increas-
ing the GC content provides better mRNA stability, processing, 
and nucleocytoplasmic transport. Since we have previously 
indicated the moderate superiority of GK/pCI vaccine over the 
K3/pCI vaccine (20), it was of interest to check the effects of the 
NFGK/pCI variant of vaccine, containing both, the κB motifs 
and the sequence of HA with the increased percentage of GC 
in the third position (GC3). One could expect that NFGK/pCI 
DNA vaccine would be the highly immunogenic. Apparently, 
we have not observed an anticipated improvement of humoral 
response after applying of the NFGK/pCI vaccine. Presumably, 
the large amounts of plasmid DNA or an intracellular protein 
antigen (translated from the expression cassette provided by 
the DNA vaccine) might generate too vigorous cellular immune 
response which kills off the transfected cells too early to maintain 
immune stimulation, thereby resulting in attenuated vaccine 
response (28, 29).
The immunological humoral responses induced by the 
tested plasmids seem to work differently in the used animal 
models and they slightly vary depending on the experiment. 
In chickens, the 3NF/pCI worked better than K3/pCI, while a 
single immunization trial with NFGK/pCI (only in Experiment 
3; Figure  1) failed to show its superiority or inferiority (see 
the above paragraph). The highest ELISA antibody levels were 
induced by the 3NF/pCI plasmid similarly in three independ-
ent immunization trials, although not all experiments gave 
results that passed rigorous statistical tests verifying differences 
between the groups that received the plasmid with and without 
the κB sites. Moreover, the lack of low responders in 3NF/pCI 
groups suggest that the addition of κB sites could increases the 
chances of responding to vaccination, what is very desirable. 
Both, the HI titers and the IgY endpoint titers were higher in 
the 3NF/pCI groups than in the K3/pCI groups, confirming 
that the presumed more effective nuclear entry of the modified 
plasmid can indirectly improve immunogenicity of the vaccine. 
Furthermore, some differences in the strength and dynamics 
of the responses observed in different experiments might 
be attributed to the different genetic backgrounds of the two 
chicken lines used, as well as their metabolism, growth, and 
development, which are the results of intensive genetic selection 
(30). So far, not many studies have been performed on immuno-
logical differences between the broiler and layer chicken lines. 
In the experimental vaccination studies, usually the SPF White 
Leghorn breed is used, thus this is one of the very first reports 
studying the humoral response to a DNA vaccine in layer and 
broiler chickens.
In mice, the differences between the variants of DNA vaccine 
at humoral level were much less pronounced than in chickens, 
probably because mice are not the natural host of influenza virus. 
However, in Experiment 1 (Figure 2), the humoral response in 
3NFGK/pCI group is significantly better than that in K3/pCI group 
on day 56. The subsequent assays, such as monitoring the level of 
cytokines secreted by stimulated splenocytes (isolated 2  weeks 
after the booster) and the percentage of Tc and Th population and 
their CD25+ and CD69+ subpopulations, might also suggest that 
the compared variants of the DNA vaccine differentially affect 
mice immune responses in the spleen. However, high individual 
variability does not allow us to draw strong conclusions about 
differences between the immunized groups.
The very low (at the detection limit, not shown) levels of 
IL-2, IL-6, and IL-10 and absence of IL-4 and IL-17a might 
be explained by the conditions of the assay and splenocytes 
cultivation (and induction), which were optimal for IFN-γ, and 
also by the short half-life of IL-4 (31) and by the high concen-
tration of IFN-γ, which negatively regulates the induction of 
Th17 cells (32).
Comparison of the transcriptional patterns of splenocytes 
isolated from mice immunized with the two types of vaccine (K3/
pCI and 3NF/pCI) with the transcriptional pattern of the control 
mice (pCI) revealed some differences between the variants. For 
example, differences in the transcripts level of two microRNA 
were detected (Table S2 in Supplementary Material): mir181-b 
was downregulated in the 3NF/pCI, while mir1186 was down-
regulated in K3/pCI. Interestingly, mir181-b inhibits the expres-
sion of importin-α3 that is crucial for translocation of NF-κB 
from cytoplasm to nucleus. The level of mir181-b is reduced after 
proinflamatory stimulation, e.g., by TNF-α and the transcription 
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of NF-κB-dependent genes can be activated (33). Unfortunately, 
little is known about function of mir1186 but it is suggest that its 
upregulation might stimulate cell proliferation (34).
Expression of two genes (Apol11b and Lyst) has been positively 
verified by RT-qPCR. Information about the function of Apol11b 
and Lyst, two genes with the expression verified by RT-qPCR, 
is rather limited. The Apol11b gene, upregulated in both tested 
groups (3NF/pCI and K3/pCI), encodes the Apolipoprotein 
L variant specific for the spleen (35). Apolipoproteins L share 
functional similarities with proteins of the Bcl-2 family, taking 
part in the regulation of apoptosis, and are encoded by genes 
induced under inflammatory conditions, i.e., type-1 INF. The 
second gene downregulated in the 3NF/pCI group (but not in 
the K3/pCI group) was LYST, a lysosomal trafficking regulator. 
A deficiency in this gene results in the enlargement of lysosomes 
with abnormal morphology in granulocytes and some other 
leukocytes (36). Recent data suggest that the LYST protein 
might be required for the maturation of perforin-containing 
granules into exocytosis-competent secretory granules (37). 
Moreover, silencing of the Lyst gene results in the induction 
of apoptosis in RPMI 8226 myeloma cells (38). Based on these 
findings, it can be hypothesized that vaccination with 3NF/pCI 
facilitates and enhances the immune response in comparison 
to the vaccination with K3/pCI. This is reflected in increased 
apoptosis, resulting in the removal of immune effector cells that 
have fulfilled their function and leading to immune response 
silencing, thereby protecting the vaccinated organism from 
uncontrolled inflammatory and enabling the preservation of 
homeostasis (39). This assumption is in agreement with the 
dynamics of humoral responses, since a substantial increase in 
induced antibodies was observed earlier in the 3NF/pCI group 
than in the K3/pCI group.
Despite extensive work on DNA vaccines, reports describing 
usage of the binding sites for nuclear factors as stimulators of 
antigen expression and enhancers of the immune response are 
quite limited. Results of our study highlight possible positive 
effects of such modifications on the effectiveness of DNA vaccine. 
However, extended analysis of the mechanisms responsible for 
the observed effects is needed before such modifications can be 
put into practice and used for development of highly immuno-
genic and safe DNA vaccines.
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